These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3943113)

  • 21. [Dose factors/time factors in chemotherapy].
    Philip T; Bouffet E; Biron P; Brunat-Mentigny M
    Bull Cancer; 1989; 76(9):979-94. PubMed ID: 2695186
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aminothiadiazole: an antineoplastic thiadiazole.
    O'Dwyer PJ; Wagner BH; Stewart JA; Leyland-Jones B
    Cancer Treat Rep; 1986 Jul; 70(7):885-9. PubMed ID: 2872957
    [No Abstract]   [Full Text] [Related]  

  • 24. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of platinum compounds and their possible combination.
    Pasetto LM; D'Andrea MR; Brandes AA; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):59-75. PubMed ID: 16806960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Reynolds CP; Maurer BJ
    Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teniposide: a review of 12 years of experience.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
    Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
    [No Abstract]   [Full Text] [Related]  

  • 28. Confidence interval about the response at the stationary point of a response surface, with an application to preclinical cancer therapy.
    Carter WH; Chinchilli VM; Campbell ED; Wampler GL
    Biometrics; 1984 Dec; 40(4):1125-30. PubMed ID: 6534413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to "use of Statistics when Examining Lifetime Studies in Rodents to Detect Carcinogenicity".
    Fears TR; Tarone RE
    J Toxicol Environ Health; 1977 Nov; 3(4):629-32. PubMed ID: 592430
    [No Abstract]   [Full Text] [Related]  

  • 32. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple drug chemotherapy combined with multiple fractions per day (MFD) radiotherapy in an experimental solid tumor model.
    Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
    In Vivo; 1994; 8(1):107-12. PubMed ID: 8054501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 36. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
    Rose WC
    J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of cancer chemotherapy: experimental and clinical approaches.
    Antibiot Chemother (1971); 1980; 28():1-185. PubMed ID: 6998357
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
    Gasparini G; Longo R; Fanelli M; Teicher BA
    J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
    Leonetti C; Scarsella M; Riggio G; Rizzo A; Salvati E; D'Incalci M; Staszewsky L; Frapolli R; Stevens MF; Stoppacciaro A; Mottolese M; Antoniani B; Gilson E; Zupi G; Biroccio A
    Clin Cancer Res; 2008 Nov; 14(22):7284-91. PubMed ID: 19010844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.